Observational studyWorld journal of surgical oncology2025
Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Yinfang Gu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.